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A Multinational Analysis of 
Mutations and Heterogeneity in 
PZase, RpsA, and PanD Associated 
with Pyrazinamide Resistance in M/
XDR Mycobacterium tuberculosis
S. M. Ramirez-Busby1, T. C. Rodwell2, L. Fink1, D. Catanzaro  3, R. L. Jackson2, M. Pettigrove2, 
A. Catanzaro2 & F. Valafar1
Pyrazinamide (PZA) is an important first-line drug in all existing and new tuberculosis (TB) treatment 
regimens. PZA-resistance in M. tuberculosis is increasing, especially among M/XDR cases. Noted issues 
with PZA Drug Susceptibility Testing (DST) have driven the search for alternative tests. This study 
provides a comprehensive assessment of PZA molecular diagnostics in M/XDR TB cases. A set of 296, 
mostly XDR, clinical M. tuberculosis isolates from four countries were subjected to DST for eight drugs, 
confirmatory Wayne’s assay, and whole-genome sequencing. Three genes implicated in PZA resistance, 
pncA, rpsA, and panD were investigated. Assuming all non-synonymous mutations cause resistance, 
we report 90% sensitivity and 65% specificity for a pncA-based molecular test. The addition of rpsA and 
panD potentially provides 2% increase in sensitivity. Molecular heterogeneity in pncA was associated 
with resistance and should be evaluated as a diagnostic tool. Mutations near the N-terminus and 
C-terminus of PZase were associated with East-Asian and Euro-American lineages, respectively. Finally, 
Euro-American isolates are most likely to have a wild-type PZase and escape molecular detection. 
Overall, the 8–10% resistance without markers may point to alternative mechanisms of resistance. 
Confirmatory mutagenesis may improve the disconcertingly low specificity but reduce sensitivity since 
not all mutations may cause resistance.
Pyrazinamide (PZA) is an important first-line drug recommended by the World Health Organization (WHO) 
for treatment of tuberculosis (TB)1. Although most patients diagnosed with TB are successfully treated with 
first-line drugs, rifampicin (RIF), isoniazid (INH), ethambutol, and PZA, the incidence of multidrug resistant 
TB (MDR-TB) (resistant to first-line drugs) is increasing every year1. Along with this rate, the incidence of PZA 
resistance (PZAR) is also increasing since over 60% of MDR-TB cases globally are also PZAR (rates vary region-
ally)2. In this manuscript we denote isolates that are resistant or susceptible to PZA by growth-based drug suscep-
tibility testing (DST) as PZAR or PZAS, respectively.
PZA is unique among anti-TB drugs in that, while it demonstrates powerful in vivo sterilizing activity, it 
exhibits no activity against actively growing Mycobacterium tuberculosis bacilli under normal culture conditions 
at neutral pH3. The drug appears to preferentially act against non-replicating persisters with low metabolic activ-
ity at acid pH in vitro or in vivo4.
Importantly, most new drug regimens proposed for treatment of drug-resistant TB (DR-TB) show improved 
outcomes when combined with PZA5–9. Although growth-based PZA susceptibility testing is recommended by 
the WHO10, the method yields inconsistent results in some cases and suffers from a relatively high false resistance 
rate11.
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While DST is the recommended method for determining resistance to all first- and second-line drugs1, 
because of PZA-specific challenges, WHO is currently considering pncA-based molecular diagnostics as the rec-
ommended approach. In this study we examine the performance of such a platform in detection of PZA resist-
ance among M/XDR TB cases from four high-TB burden countries. We also examine how the inclusion of the 
other two frequently discussed genes, panD and rpsA, would improve the proposed platform.
The protein commonly associated with PZA resistance is pyrazinamidase/nicotinamidase (PZase) encoded by 
the gene pncA12. Mechanistically, PZA is a pro-drug that requires activation by PZase. PZase converts PZA into 
pyrazinoic acid (POA), where it is actively driven out of the cell, extracellularly protonated, and passively diffused 
back in, eventually acidifying and killing the bacterium4, 13. Hundreds of mutations distributed across pncA and 
its promoter have been associated with resistance, however some are also harbored by susceptible strains14, 15. 
This is unique since resistance to other drugs can usually be explained by a handful of mutations16–18. A recent 
systematic review estimated mutations in pncA and its promoter provide a global sensitivity and specificity of 83% 
and 90%, respectively14.
While changes in PZase have been associated with PZA resistance, several studies have observed PZAR iso-
lates with a wild-type (WT) pncA19–23, highlighting the need for discovery of new markers that could be used in 
molecular diagnostics. Recently, mutations in 30 S ribosomal protein S1 (rpsA) and aspartate 1-decarboxylase 
precursor (panD) have been reported to be associated with PZA resistance in M. tuberculosis24, 25.
The gene rpsA encodes a protein involved in trans-translation, a mechanism that rescues stalled ribosomes 
and tags truncated proteins for degradation24. Zhang et al. demonstrated that overexpression of rpsA in M. tuber-
culosis confers PZA resistance in vitro24.
The gene panD converts L-aspartate into β-alanine, a precursor in the anabolism of coenzyme A (CoA)25. 
Laboratory generated strains of PZAR M. tuberculosis were observed with mutations in panD, yet WT-pncA25. 
However, subsequent studies have rebutted rpsA and panD as potential targets of PZA resistance26, 27.
In this study, we considered 296 mostly M/XDR-TB patients from four high-burden TB countries: India, 
Republic of Moldova, the Philippines, and South Africa. Unlike previous systematic reports, we have ensured 
standardized phenotyping for eight first and second line drugs, including PZA, using BACTEC MGIT 960 DST28. 
Additionally, we have performed PZase enzymatic activity testing using Wayne’s assay to confirm DST results. 
Genotyping was also performed via amplification-free long-read whole-genome sequencing for each isolate. 
Mutations in pncA, rpsA, and panD and their promoters were investigated for association to phenotypic PZA 
resistance.
Results
Phenotypic testing. Out of 296 mostly XDR-TB isolates (Table 1), 224 were PZAR and 72 were PZAS by 
DST. Two isolates were PZA mono-resistant. Table 1 also displays the prevalence of PZA resistance in all pheno-
typic categories.
In all, 47 (16%) strains (22 PZAR and 25 PZAS) had discordant phenotypic-genotypic results (i.e. PZAS with 
a mutant pncA or promoter, or PZAR with a WT pncA or promoter—Supplementary Table ST1) and underwent 
further enzymatic characterization.
PZA Phenotype Lineage
Pan-
Susceptible Mono MDR
Pre-
XDR XDR Other
All (296) All (296) 19 8 16 36 207 10
Resistant (224) All Lineages (224) 0 3 11 26 179 5
East Asian (Beijing) 
(115) 0 0 1 10 103 1
East Asian (1) 0 0 0 1 0 0
Indo-Oceanic (18) 0 1 6 2 6 3
Euro-American (81) 0 1 4 13 63 0
East-African Indian 
(CAS) (9) 0 1 0 0 7 1
Susceptible (72) All Lineages (72) 19 5 5 10 28 5
East Asian (Beijing) 
(21) 2 1 1 4 12 1
East Asian (0) 0 0 0 0 0 0
Indo-Oceanic (16) 6 3 2 4 0 1
Euro-American (31) 9 1 1 2 16 2
East-African Indian 
(CAS) (4) 2 0 1 0 0 1
Table 1. Drug susceptibility patterns per lineage among the GCDD M. tuberculosis clinical isolates. Numbers in 
parentheses indicate total isolate counts for each category. PZA: pyrazinamide; MDR-TB: resistant to isoniazid 
and rifampicin, only; XDR-TB: MDR-TB that is also resistant to at least one fluoroquinolone and one injectable; 
pre-XDR-TB: MDR-TB and resistant to either a fluoroquinolone(s) or an injectable(s); Pan-Susceptible: 
susceptible to all seven (INH, RIF, CAP, AMK, KAN, OFX, MOX) drugs tested; Mono: isolates resistant to only 
one of the seven study drugs; Other: isolates with unusual phenotypic patterns such as susceptibility to INH but 
resistance to second line drugs.
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Enzymatic activity. Overall, 103 isolates (79 PZAR and 24 PZAS), including 44 (22 PZAR and 22 PZAS) of 
the 47 phenotypic-genotypic discordant isolates, were tested for enzymatic activity (Table 2). Of the 103 tested 
isolates, five (5%) (one PZAR and four PZAS) had discordant DST and Wayne’s assay results. The DST results of 
41 of the 44 phenotypic-genotypic discordant isolates were confirmed by Wayne’s assay. Only three PZAS isolates 
had a discordant DST and enzymatic activity results (Table 2).
Mutations in pncA of PZAR Isolates. Of the 224 PZAR isolates, 202 harbored a non-synonymous mutation 
in pncA and/or its promoter. Of these, 195 isolates (87%) harbored a mutation only in the gene, four (2%) only in 
its promoter, and 3 (1%) in both. The two PZA mono-resistant isolates belonged to the first group. Synonymous 
mutations in the coding region were ignored in our analyses. Those isolates that only harbored a synonymous 
mutation in a gene were labeled as having a WT protein in this study. Supplementary Table ST2 provides a com-
prehensive list of all mutations harbored by all isolates. Importantly, 22 PZAR isolates (10%) had a WT pncA gene 
and promoter. All 22 tested negative for PZase activity (Table 2 and Supplementary Table ST2). These 22 isolates 
were not part of the same clonal expansion (based on the lineage typing) (Supplementary Table ST2).
In 224 PZAR isolates, we observed 136 unique protein-altering polymorphisms in pncA and 6 unique muta-
tions in its promoter. Of these, 40 polymorphisms in the gene and three (all indels) in the promoter had not been 
previously reported and are referred to here as novel mutations (Supplementary Table ST3)14.
The distribution of mutations across the gene is shown in Fig. 1. The most variable locus was codon 14 (Fig. 
1a). Two variants were observed in the codon, Cys14Arg and Cys14STOP. Cys14Arg was the most frequently 
PZA DST Result PZase Positive PZase Negative
Resistant 1 (0) 78 (22)
Susceptible 20 (19) 4 (3)
Table 2. Results of the Wayne’s pyrazinamidase (PZase) activity assay for 103 (including 44 pncA genotypic-
phenotypic discordant) clinical M. tuberculosis isolates. Drug susceptibility was determined by BACTEC 
MGIT 960. Numbers in parentheses indicate the number of isolates with discordant PZA phenotype and 
pncA genotypic (i.e. resistant isolates with WT pncA and promoter or susceptible isolates with mutant pncA or 
promoter).
Figure 1. Distribution of pncA mutations in (a) PZAR and (b) PZAS clinical M. tuberculosis isolates. 
Frequencies labeled as “Heterogeneous” represent calls that had sufficient support for both a variant and 
the reference, indicative of mixed populations. “Monoclonal” frequencies represent calls that were clearly 
supportive of a variant. The frequencies presented here are the totals over all the different mutations observed at 
each codon.
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observed mutation (20 isolates from South Africa). Eighteen had identical MIRU-VNTR and spoligotyping pat-
terns suggesting a clonal expansion (East-Asian, Beijing sublineage). Cys14STOP was observed in one isolate 
from Moldova and belonged to the Euro-American lineage.
Mutations in pncA of PZAS isolates. Of the 72 susceptible isolates, 25 harbored a mutation in the coding 
region of pncA and/or in its promoter (Table 3 and Fig. 1b). Twenty-six (22 coding and 4 promoter) unique muta-
tions in pncA of PZAS isolates were observed. Of the coding region mutations, 13 were novel, and of the promoter 
mutations, 2 were novel (Supplementary Table ST4). The most frequent non-synonymous polymorphism was 
Thr47Ala, occurring in three PZAS isolates, all of which tested positive for PZase activity (Fig. 1b).
Lineage-based Analysis of pncA mutations. Supplementary Figure SF1 depicts lineage-based stratifi-
cation of mutations observed in pncA, both in resistant and susceptible isolates. The gene and its promoter were 
divided into seven “zones” and prevalence of mutations in isolates from each lineage was assessed. The results of 
this analysis are shown in Supplementary Table ST5. Most notable was the relatively high percentage (15%) of 
Euro-American PZAR isolates with WT pncA and promoter. Furthermore,”hot spots” were observed in specific 
lineages: codons 1–30 for East-Asian, 121–150 for Indo-Oceanic, and codons 151 and higher for Euro-American. 
Similarly, there appears to be “cold spots” (31–60 for East-Asian and codons 91–120 for Euro-American), where 
very few isolates from these lineages harbored a mutation. Finally, the range between codons 91 and 120 seems 
to be a cold spot for all lineages, except for East-Asian. These patterns need to be confirmed in larger cohorts.
Mutations in rpsA. Twenty PZAR and eight PZAS isolates harbored a mutation in RpsA (18 PZAR, seven 
PZAS) or rpsA’s promoter (2 PZAR, 1 PZAS) region (Supplementary Table ST2). Of these 14 PZAR and 4 PZAS 
isolates only had heterogeneous mutations in the rpsA and its promoter. Of the 22 resistant isolates without a 
mutation in pncA or its promoter, three had a heterogeneous, non-synonymous mutation in rpsA (deletion of 
C in nucleotide 660, deletion of a C in nucleotide 1065 [novel], and deletion of a C in nucleotide 1142 [novel]). 
The three showed no PZase activity on Wayne’s assay and had no mutations in panD. The most frequent rpsA 
variant was the previously reported synonymous change, Arg212Arg (99 PZAR and 20 PZAS isolates)26. This 
mutation has been identified as a Lineage 2 (East-Asian) marker. In our set, this mutation was harbored by three 
Euro-American isolates as well (Supplementary Table ST6)29.
Mutations in panD. Previous studies have reported panD to be a potential target for PZA25, 30. In this study, 
no monoclonal mutations were found in panD’s promoter or coding region. Of the PZAR isolates without a muta-
tion in pncA, one had a heterogeneous mutation in panD (-G291) (Supplementary Table ST2). This isolate showed 
no PZase activity.
Resistant Cases with WT promoter and coding regions in the three genes. Eighteen PZAR isolates 
had no mutations in the promoter or the enzyme of the three genes considered in this study. All tested negative 
for enzymatic activity. Nine of the 18 belonged to Euro-American lineage, while eight were East-Asian (Beijing), 
and one was Indo-Oceanic.
Heterogeneous Populations in pncA. The mutation counts reported here also include heterogeneous 
variants. Mixed populations were detected in pncA (coding and promoter region) of 40 isolates (34 PZAR, 6 
PZAS) (Supplementary Tables ST7 and ST2). In 13 of the 34 PZAR isolates, the heterogeneous variant was the only 
polymorphism in the three genes. Nine heterogeneous variants were observed in the 13 isolates (Supplementary 
Table ST8). The most frequent of these variants was the novel insertion of C in nucleotide 453 which was observed 
in five resistant isolates. Three belonged to East-Asian, three belonged to Indo-Oceanic, two belonged to CAS, and 
one was Euro-American, ruling out the possibility of clonal expansion. In rpsA (coding and promoter region), 
21 isolates (16 PZAR, 5 PZAS) had heterogeneous calls, and in panD, 11 isolates (8 PZAR, 3 PZAS) exhibited this 
Category pncA panD rpsA
PZAR with mutant enzyme* 195 7 19
PZAR with mutant promoter 
(but WT enzyme†) 4 1 1
PZAR with mutant promoter 
and enzyme 3 0 0
PZAR with WT enzyme† and 
promoter 22 216 204
PZAS with mutant enzyme* 19 1 7
PZAS with mutant promoter 
(but WT enzyme†) 6 2 1
PZAS with mutant promoter 
and enzyme 0 0 0
PZAS with WT enzyme† and 
promoter 47 69 64
Table 3. Frequency of mutations in pncA and its promoter, panD and its promoter, and rpsA and its promoter 
in M. tuberculosis clinical isolates. WT = wild-type. *Includes heterogeneous variations (i.e. mixed populations 
with mutant and WT gene/promoter). †Also includes isolates that harbor synonymous mutations (only) in the 
gene.
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behavior. No isolate had heterogeneity in more than one of the studied genes. The frequency of a heterogeneous 
observation in pncA of PZAR isolates was notably higher than that of PZAS isolates (15% resistant versus 8% 
susceptible). These frequencies were (7% versus 7%) for rpsA and (4% versus 4%) for panD (Supplementary 
Table ST7).
Discussion
This multinational study is based on strains collected from pulmonary TB patients in four high burden countries. 
Our primary objective was to determine the accuracy of a molecular test to diagnose PZA resistance in our set of 
MDR- and XDR-TB patients from high TB burden regions. Three genes, pncA, rpsA, and panD, were considered 
in this study. Although each gene has been well-studied independently, a concurrent assessment of all three in 
MDR- and XDR-TB patients from multiple high-burden countries has been limited.
Correlation with resistance to other drugs. Among our isolates, broader resistance to other drugs 
directly translated to higher prevalence of PZA resistance. None of our isolates that were susceptible to the other 
seven drugs were PZAR, while 38% of those mono resistant to one of the other drugs, 69% of MDR isolates, and 
86% of XDR isolates were PZAR (Supplementary Figure SF2). While it is known that PZA resistance is associated 
with MDR status2, such a direct relationship to the breadth of resistance to second line drugs, beyond MDR, is less 
established and should be investigated further in larger cohorts.
Phenotypic accuracy. Both false resistance and susceptibility have been noted for MGIT PZA DST in lit-
erature. The prevalence of false resistance, however, has been reported to be unusually high11. Over-inoculation 
is a common cause of false resistance and is a frequently the suspected reason for phenotypic-genotypic discord-
ance31, 32. Using orthogonal confirmation (see the Phenotyping section in Methods), we confirmed lack of enzy-
matic activity in all 22 phenotypic-genotypic discordant PZAR isolates (with WT pncA and promoter) (Table 2). 
We were also able to establish the presence of enzymatic activity in 19 of the 22 phenotypic-genotypic discordant 
PZAS isolates (with a mutant pncA) (Table 2). Overall, we observed 95% concordance between DST and enzy-
matic activity (Cohen’s Kappa = 0.86). (Table 2) Majority of discordant cases (4 out of 5) were susceptible isolates 
with a mutant pncA. We hypothesize that this relates to mutations that do not cause a disruption in enzymatic 
activity or do so minimally causing low level resistance undetectable by the current cutoff. (Please see the sections 
on Sensitivity/Specificity and Causation).
Novel pncA mutations. Overall 43 of the 142 (30%) unique variants observed in pncA of our PZAR iso-
lates were previously not reported. (Supplementary Table ST3) Similarly, 15 of the 26 (58%) variants observed 
in pncA of our PZAS isolates were novel. The high percentage of novel pncA variants is not unusual. The variable 
nature of the gene is well documented and hundreds of unique mutations have already been reported2, 14, 23, 33. The 
notably higher rate of novel variants observed in PZAS isolates is new. This may reflect a bias toward sequencing 
resistant isolates in the past—a practice that needs to change since an accurate catalog of mutations not associated 
with resistance is essential for molecular diagnostics. Among others, Whitfield et al. reported 10 pncA mutations 
that do not confer PZA resistance at the cut off of 100 mg/L34. Here, we add 15 more polymorphisms to the list 
(Supplemental Table ST4).
Sensitivity/specificity. A wide range of sensitivities have been regionally reported for pncA mutations, 
ranging from 45.7% in Rio de Janeiro35 to 93% in China36. We report 90.2% (202/224) concordance between 
pncA genotype and phenotype among our resistant isolates. This is in line with some previous reports11, 26, 37, and 
higher than the global sensitivity of 83%14. A wide range of specificities has also been reported in the literature. 
For example, Osman et al. reported a specificity of 63% for pncA mutations38, while, Juréen et al. reported a spec-
ificity of 97.3% in China36. We report a specificity of pncA-based diagnostics in our study at 65% (25/72 PZAS 
isolates had a mutant pncA or promoter) which is notably lower than the global specificity of 90%14, but within 
the reported regional ranges14, 23, 39. It is known that not all changes affect the function of the enzyme significantly. 
The lower specificity in our study is due to the large number of novel pncA polymorphisms observed in our PZAS 
isolates. Since the phenotype has been confirmed by the enzymatic activity, as mentioned, we believe that these 
mutations either do not change the function of the enzyme or do so minimally causing low levels of resistance 
below MGIT cutoff.
An important note about the sensitivity and specificity reported here is that these percentages depend on the 
criteria used for their calculation. Several such criteria have been proposed in the literature. The most common, 
and one that we have used, employs all pncA promoter or PZase variants as a marker for resistance. This provides 
the highest sensitivity but low specificity. Alternatively, all mutations observed in susceptible isolates could be 
excluded, providing 100% specificity but dramatically reducing sensitivity from 90% to 65% (146/224) in our 
study. Miotto et al.23 propose a few different criteria, all of which would produce percentages between the two 
extremes calculated here. For instance, excluding mutations over 20 base pairs transcriptionally upstream of the 
gene would improve specificity from 65% to 70% but reduce sensitivity below 90%. The choice of this criterion 
will have important implications for molecular diagnostic platforms.
Lineage trends. Several trends can be noted in Supplementary Table ST5. Perhaps the one bearing most 
significance is that the Euro-American lineage is the most likely to escape molecular diagnostics, as it has the 
highest percentage (15%) of resistant isolates without a mutation in pncA or its promoter. Furthermore, the hot 
spot regions identified could indicate regional convergent evolution associated with PZA resistance.
Role of rpsA. The gene rpsA has held a hotly debated position within the literature, as there have been 
multiple publications both supporting and dismissing the gene’s role in PZA resistance24, 26, 40, 41 While the 
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trans-translational function of rpsA was shown to be inhibited by PZA (thought to explain PZA resistance in 
isolates without a pncA mutation)24, Alexander et al. were not able to find any phenotypically informative muta-
tions in the gene26. Regardless, due to low prevalence, the predictive value of rpsA as an indicator for PZA resist-
ance tends to be relatively low. In this study, only three heterogeneous frameshifts in rpsA (-C1065, -C1142, and 
-CA660) could potentially hold the molecular basis for otherwise unexplained resistant cases (Supplementary 
Table ST2). All three were novel and their causal role in resistance needs to be confirmed. Assuming a causal role 
for all three mutations, the diagnostic sensitivity of RpsA was around 1% (3/224) in this study.
Role of panD. Similarly, mutations in panD have been associated with PZA resistance in isolates with a WT 
pncA25, 30. We only observed one such potential case. Dillon et al. postulated that media supplemented with pan-
tothenate, certain pantothenate analogs, or other metabolites likely explained the PZA resistance of strains with 
mutations in panD27. The authors proposed that PZA resistance was independent of mutations in panD.
Causation. Generally, all changes in PZase are associated with PZA resistance4, 12, yet this is not true for 
all mutations14, 23. Some changes may still render a functional enzyme42, 43, leading to low level resistance. 
Understanding the effects of these changes on the enzyme is crucial. Furthermore, the prevalence of unexplained 
resistance cases is currently likely underestimated since laboratory confirmation of the role of most variants in 
resistance is still lacking. This work could identify polymorphisms that do not play a role in resistance, or cause 
low levels of resistance well below the cutoff, adding to the number of unexplained resistance cases. As such, the 
causal role of all pncA, rpsA, and panD mutations in resistance should be experimentally confirmed in M. tuber-
culosis, similar to studies performed on inhA44, katG45, rpoB46, 47, and gyrA48, 49.
Alternative mechanisms. In this study, 18 PZAR isolates lacked any polymorphisms in the three genes. 
Other studies have also reported such resistant cases14, 23. A complementary or alternative mechanism of resist-
ance, other than rpsA and panD, is most frequently suspected. A complementary mechanism regulating expres-
sion of PZase would explain the resistant cases with a WT gene. rpsA and panD do not adequately address this 
problem since both are considered targets of POA (activated form of PZA by PZase)24, 25, 27. Such a mechanism has 
proven to be elusive in spite of efforts in a number of laboratories around the world.
Heterogeneity. Chemotherapy in a host with mixed bacterial population selects for the resistant subpop-
ulation50. Undetected heterogeneity could be an explanation for unexplained resistant cases. Using our WGS 
approach, we were able to detect low levels of heteroresistance, closer to the sensitivity of MGIT DST (10%)51. 
It is still possible that some unexplained resistance cases are due to existence of small resistance subpopulation 
detectable by DST but not by our WGS. Heterogeneity, as detected by our approach, seemed to be a random event 
in panD and rpsA with equal frequencies among resistant and sensitive isolates (Supplementary Table ST8). In 
pncA, however, heterogeneity had a notably higher frequency (nearly two-fold) among resistant as compared to 
susceptible isolates with a diagnostic specificity of 92% (Supplemental Table ST7). The association of heteroge-
neity with phenotypic resistance and its utility in diagnostics needs to be investigated in a larger cohort. In this 
study, we considered resistant cases with heterogeneous pncA mutations as explained cases.
Conclusion
A diagnostic approach, based on all pncA mutations, seems to be more appropriate than any selective criterion 
suggested in the literature as a diagnostic platform would err more on the false resistance side. While pncA as a 
whole demonstrated high association with PZA phenotype, rpsA and panD did not among our isolates and else-
where52. The existence of 18 PZAR isolates lacking PZase activity with WT promoter and coding regions of the 
three genes may suggest a missing regulatory component in the currently understood mechanism of resistance. 
The high number of novel variations in PZase of PZAS isolates may suggest an undersampling of PZA-susceptible 
XDR-TB isolates in sequencing. For a comprehensive picture of the pncA genotype, this needs to be corrected. 
We also demonstrated that heterogeneity in pncA may not be a random event and that there are lineage-specific 
patterns among pncA mutations.
Overall, the results of this study demonstrate that a molecular diagnostic platform may suffer from a notable 
false resistance or false susceptibility error rate among MDR- and XDR-TB cases. In high TB burden countries 
this would introduce a non-negligible number of misdiagnosed cases.
Materials and Methods
Isolate Selection. M. tuberculosis strains were isolated from patient sputum in four countries (India, 
Moldova, Philippines, and South Africa). This effort was performed as part of a separate project called the Global 
Consortium for Drug-resistant tuberculosis Diagnosis (GCDD)53. Details of patient selection and sample col-
lection methodology are described by Garfein et al.28 and in the Supplementary Methods. All sequencing and 
phenotypic data was downloaded from the publically available repository on NCBI (BioProject: PRJNA353873).
MIRU-VNTR, Spoligotyping, and Lineage Determination. Genotyping using mycobacterial inter-
spersed repetitive units variable number of tandem repeats (MIRU-VNTR) and spoligotyping were described by 
Garfein et al.28. Lineage determination based on MIRU and spoligo information was also described by Garfein et 
al.28. A brief summary is provided in the Supplementary Methods.
Phenotyping. All isolates were tested for phenotypic resistance to seven first- and second-line drugs, INH, 
RIF, three injectable antibiotics (kanamycin, amikacin, capreomycin), and two from the quinolone group of drugs 
(moxifloxacin and ofloxacin). DST results for these drugs have been previously published by Garfein et al.28. 
Standard BACTEC MGIT 960 methods were performed using WHO recommended critical concentrations.
www.nature.com/scientificreports/
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PZA susceptibility testing was performed on BACTEC MGIT 960 for this study. Isolates with discrepant phe-
notypic and pncA genotypic results were further examined for PZase activity54. A brief description of both sus-
ceptibility testing and enzyme activity is located in the Supplemental Methods.
To test the validity of our phenotypic results we explored two common validation approaches: parallel and 
orthogonal testing. Parallel testing would require the DST to be repeated while orthogonal testing would require 
an independent method with an independent error profile as compared to that of MGIT DST, such as Wayne’s 
enzymatic assay. Its error profile is the opposite of DST: higher false sensitivity rates but much lower false resist-
ance rates55. Because this study aims to identify molecular markers that can be used for diagnosis of resistance, 
we chose the orthogonal approach for its lower likelihood of false resistance error. A wide range of rates for false 
resistance has been reported for PZA DST with some as high as 60%32, 56, 57. Recently this rate was estimated to be 
at 11.3% by Murray et al.58. The parallel approach with a repeat DST, therefore, would have ~1% false resistance 
rate (assuming a white noise, nonsystematic, random error event—otherwise higher) when both results agree. 
Wayne’s assay has a 3% false resistance rate as most of its errors belong to the false sensitivity category55. As such, 
orthogonal testing has a false resistance rate of 0.3% (1/3 that of the parallel approach) when the results of both 
tests agree. Additionally, since it has not yet been established whether the false resistance rate of DST is a problem 
with the method or a characteristic of certain isolates (e.g. “flip-flopping” between multiple DST results), orthog-
onal testing allows the separation and investigation of the two potential causes.
Whole-Genome Sequencing. Sample and library preparation and post-sequencing analysis are described 
in the Supplementary Methods. Base calling was performed by consideration of reads supporting major and 
minor variants. Positions with a minor variant were labeled as “heterogeneous”, otherwise, the position was 
considered “monoclonal”. Minor variants were called using the criterion suggested by Black et al.59. For 
genotypic-phenotypic analysis we considered heterogeneous populations (in positions of consequence) as resist-
ant since a mutant subpopulation was detected.
For this study, we considered the promoter (200 base pairs transcriptionally upstream from the annotated 
start site) and the coding regions of three genes: pncA (rv2043c), rpsA (rv1630), and panD (rv3601c). The 
genome positions for the six regions based on H37Rv reference (GenBank accession NC_000962.3) are listed 
in Supplementary Table ST9. These regions were examined for presence of genomic variation using the variant 
analysis methods described above and in the Supplementary Methods.
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